Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy

Drug Resistance Updates

Volumn 10, Issue 1-2, 2007, Pages 13-29

  Maddika, Subbareddy ^a,b   Ande, Sudharsana Rao ^a   Panigrahi, Soumya ^a,b   Paranjothy, Ted ^a   Weglarczyk, Kazimierz ^a,c   Zuse, Anne ^a   Eshraghi, Mehdi ^a,b   Manda, Kamala D ^b   Wiechec, Emilia ^a,d   Los, Marek ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

Cell cycle; Cell death; Cell survival; GADD45, PUMA, NOXA, HIPK2

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN B2; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; CYCLIN DEPENDENT KINASE INHIBITOR 2D; CYCLIN E; P21 ACTIVATED KINASE 1; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P16INK4A; PROTEIN P53; PROTEIN P57; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1;

APOPTOSIS; ARTICLE; CANCER; CANCER CELL; CANCER THERAPY; CELL CYCLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HUMAN; INHIBITION KINETICS; PRIORITY JOURNAL; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; CYCLIN-DEPENDENT KINASES; CYCLINS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 34247371033     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2007.01.003     Document Type: Article

References (208)

1. Aki T., Mizukami Y., Oka Y., Yamaguchi K., Uemura K., Fujimiya T., and Yoshida K. Phosphoinositide 3-kinase accelerates necrotic cell death during hypoxia. Biochem. J. 358 (2001) 481-487
2. Aki T., Yamaguchi K., Fujimiya T., and Mizukami Y. Phosphoinositide 3-kinase accelerates autophagic cell death during glucose deprivation in the rat cardiomyocyte-derived cell line H9c2. Oncogene 22 (2003) 8529-8535
3. Alarcon R.M., Rupnow B.A., Graeber T.G., Knox S.J., and Giaccia A.J. Modulation of c-Myc activity and apoptosis in vivo. Cancer Res. 56 (1996) 4315-4319
4. Aleem E., Kiyokawa H., and Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat. Cell Biol. 7 (2005) 831-836
5. Alexander, H.C., Booy, E.P., Xiao, W., Baust, H., Ezzati, P., Los, M. Selected technologies to control genes and their products for experimental and clinical purposes. Arch. Immunol. Ther. Exp. 55, in press.
6. Ali I.U., Schriml L.M., and Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. 91 (1999) 1922-1932
7. Alvarez B., Martinez A.C., Burgering B.M., and Carrera A.C. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 413 (2001) 744-747
8. Anderson J.E., Hansen L.L., Mooren F.C., Post M., Hug H., Zuse A., and Los M. Methods and biomarkers for the diagnosis and prognosis of cancer and other diseases: towards personalized medicine. Drug Resist. Updates 9 (2006) 198-210
9. Antonsson B., and Martinou J.-C. The Bcl-2 protein family. Exp. Cell Res. 256 (2000) 50-57
10. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
11. Banerji S., and Los M. Important differences between topoisomerase-I and -II targeting agents. Cancer Biol. Ther. 5 (2006) 965-966
12. Barczyk K., Kreuter M., Pryjma J., Booy E.P., Maddika S., Ghavami S., Berdel W.E., Roth J., and Los M. Serum cytochrome c indicates in vivo-apoptosis and it can serve as a prognostic marker during cancer therapy. Int. J. Cancer 114 (2005) 167-173
13. Bernard S., and Eilers M. Control of cell proliferation and growth by Myc proteins. Results Probl. Cell Differ. 42 (2006) 329-342
14. Berthet C., Aleem E., Coppola V., Tessarollo L., and Kaldis P. Cdk2 knockout mice are viable. Curr. Biol. 13 (2003) 1775-1785
15. Biliran Jr. H., Wang Y., Banerjee S., Xu H., Heng H., Thakur A., Bollig A., Sarkar F.H., and Liao J.D. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin. Cancer Res. 11 (2005) 6075-6086
16. Bissonnette R.P., Echeverri F., Mahboubi A., and Green D.R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359 (1992) 552-554
17. Blackwell T.K., Kretzner L., Blackwood E.M., Eisenman R.N., and Weintraub H. Sequence-specific DNA binding by the c-Myc protein. Science 250 (1990) 1149-1151
18. Blagosklonny M.V., and Darzynkiewicz Z. Strategies of protection of normal cells during chemo- and radiotherapy based on modulation of cell cycle and apoptotic pathways. In: Los M., and Gibson S.B. (Eds). Apoptotic Pathways as Target for Novel Therapies in Cancer and Other Diseases (2005), Springer Science/Business Media Inc., New York 357-391
19. Booy E.P., Johar D., Maddika S., Pirzada H., Sahib M.M., Gehrke I., Loewen S.D., Louis S.D., Kadkhoda K., Mowat M., and Los M. Monoclonal and bispecific antibodies as novel therapeutics. Arch. Immunol. Ther. Exp. 54 (2006) 1-17
20. Booy E.P., Kadkhoda K., Johar D., Bay G.H., and Los M. The immune system, involvement in neurodegenerative diseases, ageing and cancer. Curr. Med. Chem-Anti-Inflamm. Anti-Allergy Agents 4 (2005) 349-353
21. Borg A., Baldetorp B., Ferno M., Olsson H., and Sigurdsson H. c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int. J. Cancer 51 (1992) 687-691
22. Borgne A., and Golsteyn R.M. The role of cyclin-dependent kinases in apoptosis. Prog. Cell Cycle Res. 5 (2003) 453-459
23. Borgne A., Versteege I., Mahe M., Studeny A., Leonce S., Naime I., Rodriguez M., Hickman J.A., Meijer L., and Golsteyn R.M. Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment. Oncogene 25 (2006) 7361-7372
24. Brouckaert G., Kalai M., Saelens X., and Vandenabeele P. Apoptotic Pathways and Their Regulation. In: Los M., and Gibson S.B. (Eds). Apoptotic Pathways as Target for Novel Therapies in Cancer and Other Diseases (2005), Springer Academic Press, New York
25. Brown J.G., and Gibson S.B. Growth factors, receptors, and kinases: their exploration to target cancer. In: Los M., and Gibson S.B. (Eds). Apoptotic Pathways as Target for Novel Therapies in Cancer and Other Diseases (2005), Springer Academic Press
26. Broxterman H.J., and Georgopapadakou N.H. Anticancer therapeutics: addictive targets, multi-targeted drugs, new drug combinations. Drug Resist. Updates 8 (2005) 183-197
27. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., and Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
28. Burke L., Flieder D.B., Guinee D.G., Brambilla E., Freedman A.N., Bennett W.P., Jones R.T., Borkowski A., Caporaso N.A., Fleming M., et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin. Cancer Res. 11 (2005) 232-241
29. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
30. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., and Reed J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
31. Carnero A., and Hannon G.J. The INK4 family of CDK inhibitors. Curr. Top. Microbiol. Immunol. 227 (1998) 43-55
32. Cassens U., Lewinski G., Samraj A.K., von Bernuth H., Baust H., Khazaie K., and Los M. Viral modulation of cell death by inhibition of caspases. Arch. Immunol. Ther. Exp. 51 (2003) 19-27
33. Catz S.D., and Johnson J.L. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostrate cancer. Oncogene 20 (2001) 7342-7351
34. Chiang C.W., Kanies C., Kim K.W., Fang W.B., Parkhurst C., Xie M., Henry T., and Yang E. Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Mol. Cell. Biol. 23 (2003) 6350-6362
35. Chipuk J.E., and Green D.R. Cytoplasmic p53: bax and forward. Cell Cycle 3 (2004) 429-431
36. Collins I., and Garrett M.D. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr. Opin. Pharmacol. 5 (2005) 366-373
37. Coqueret O. New targets for viral cyclins. Cell Cycle 2 (2003) 293-295
38. Cory S., and Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2 (2002) 647-656
39. Crews C.M., and Shotwell J.B. Small-molecule inhibitors of the cell cycle: an overview. Prog. Cell Cycle Res. 5 (2003) 125-133
40. Cuevas B.D., Lu Y., Mao M., Zhang J., LaPushin R., Siminovitch K., and Mills G.B. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J. Biol. Chem. 276 (2001) 27455-27461
41. Darzynkiewicz Z., Juan G., Li X., Gorczyca W., Murakami T., and Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 27 (1997) 1-20
42. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
43. Deng C., Zhang P., Harper J.W., Elledge S.J., and Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82 (1995) 675-684
44. Deng X., Gao F., and May Jr. W.S. Bcl2 retards G1/S cell cycle transition by regulating intracellular ROS. Blood 102 (2003) 3179-3185
45. Desbarats L., Schneider A., Muller D., Burgin A., and Eilers M. Myc: a single gene controls both proliferation and apoptosis in mammalian cells. Experientia 52 (1996) 1123-1129
46. Diehl J.A., Cheng M., Roussel M.F., and Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12 (1998) 3499-3511
47. Dobashi Y. Cell cycle regulation and its aberrations in human lung carcinoma. Pathol. Int. 55 (2005) 95-105
48. Dong J., Naito M., and Tsuruo T. c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis in human monocytic leukemia U937 cells. Oncogene 15 (1997) 639-647
49. Finkel E. The mitochondrian: is it central to apoptosis?. Science 292 (2001) 624-626
50. Finlan L.E., and Hupp T.R. The life cycle of p53: a key target in drug development. In: Los M., and Gibson S.B. (Eds). Apoptotic Pathways as Target for Novel Therapies in Cancer and Other Diseases (2005), Springer Academic Press, New York
51. Franklin D.S., Godfrey V.L., Lee H., Kovalev G.I., Schoonhoven R., Chen-Kiang S., Su L., and Xiong Y. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 12 (1998) 2899-2911
52. Frey O., and Brauer R. Regulatory T cells: magic bullets for immunotherapy?. Arch. Immunol. Ther. Exp. (Warsz) 54 (2006) 33-43
53. Fruman D.A., Meyers R.E., and Cantley L.C. Phosphoinositide kinases. Annu. Rev. Biochem. 67 (1998) 481-507
54. Gartel A.L. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk. Res. 29 (2005) 1237-1238
55. Gartel A.L., and Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 1 (2002) 639-649
56. Ghavami S., Hashemi M., Kadkhoda K., Alavian S.M., Bay G.H., and Los M. Apoptosis in liver diseases-detection and therapeutic applications. Med. Sci. Monit. 11 (2005) RA337-RA345
57. Giono L.E., and Manfredi J.J. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J. Cell. Physiol. 209 (2006) 13-20
58. Girard F., Strausfeld U., Fernandez A., and Lamb N.J. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67 (1991) 1169-1179
59. Golsteyn R.M. Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle. Cancer Lett. 217 (2005) 129-138
60. Gray N., Detivaud L., Doerig C., and Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 6 (1999) 859-875
61. Grant S., and Roberts J.D. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist. Updates 6 (2003) 15-26
62. Gregory M.A., Qi Y., and Hann S.R. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem. 278 (2003) 51606-51612
63. Greider C., Chattopadhyay A., Parkhurst C., and Yang E. BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases. Oncogene 21 (2002) 7765-7775
64. Grote J., Koenig S., Ackermann D., Sopalla C., Benedyk M., Los M., and Kerkhoff C. Identification of poly(ADP-ribose)polymerase-1 and Ku70/Ku80 as transcriptional regulator of S100A9 gene expression. BMC Mol. Biol. 7 (2006) 48
65. Guan K.L., Jenkins C.W., Li Y., Nichols M.A., Wu X., O'Keefe C.L., Matera A.G., and Xiong Y. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8 (1994) 2939-2952
66. Guo S., Rena G., Cichy S., He X., Cohen P., and Unterman T. Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J. Biol. Chem. 274 (1999) 17184-17192
67. Hakem A., Sasaki T., Kozieradzki I., and Penninger J.M. The cyclin-dependent kinase Cdk2 regulates thymocyte apoptosis. J. Exp. Med. 189 (1999) 957-968
68. Hannon G.J., and Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371 (1994) 257-261
69. Hara T., Kamura T., Nakayama K., Oshikawa K., Hatakeyama S., and Nakayama K. Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. J. Biol. Chem. 276 (2001) 48937-48943
70. Hashemi M., Ghavami S., Eshraghi M., Booy E.P., and Los M. Cytotoxic effects of intra- and extracellular zinc chelation on human breast cancer cells. Eur. J. Pharm. 557 (2007) 9-19
71. Hashemi M., Karami-Tehrani F., Ghavami S., Maddika S., and Los M. Adenosine and deoxyadenosine induces apoptosis in oestrogen receptor-positive and -negative human breast cancer cells via the intrinsic pathway. Cell Prolif. 38 (2005) 269-285
72. Hashemi M., and Kroczak T.J. Apoptosis and Autoimmune Disease. Curr. Med. Chem.-Anti-Inflamm. Anti-Allergy Agents 4 (2005) 429-438
73. Hauff K., Zamzow C., Law W.J., de Melo J., Kennedy K., and Los M. Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system. Arch. Immunol. Ther. Exp. 53 (2005) 308-320
74. Heerema N.A., Bernheim A., Lim M.S., Look A.T., Pasqualucci L., Raetz E., Sanger W.G., and Cairo M.S. State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in Childhood Lymphoma: Summary Report of Workshop at the First International Symposium on Childhood and Adolescent Non-Hodgkin Lymphoma, April 9, 2003. New York City. NY. Ped. Blood Cancer 45 (2005) 616-622
75. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
76. Hengst L., and Reed S.I. Inhibitors of the Cip/Kip family. Curr. Top. Microbiol. Immunol. 227 (1998) 25-41
77. Henriksson M., and Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res. 68 (1996) 109-182
78. Hinds P.W., Dowdy S.F., Eaton E.N., Arnold A., and Weinberg R.A. Function of a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 709-713
79. Hirai H., Roussel M.F., Kato J.Y., Ashmun R.A., and Sherr C.J. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell Biol. 15 (1995) 2672-2681
80. Hiromura K., Pippin J.W., Fero M.L., Roberts J.M., and Shankland S.J. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). J. Clin. Invest. 103 (1999) 597-604
81. Hoang A.T., Cohen K.J., Barrett J.F., Bergstrom D.A., and Dang C.V. Participation of cyclin A in Myc-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 6875-6879
82. Hsieh J.K., Yap D., O'Connor D.J., Fogal V., Fallis L., Chan F., Zhong S., and Lu X. Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol. Cell Biol. 22 (2002) 78-93
83. Hu N., Gutsmann A., Herbert D.C., Bradley A., Lee W.H., and Lee E.Y. Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9 (1994) 1021-1027
84. Huang X., Kurose A., Tanaka T., Traganos F., Dai W., and Darzynkiewicz Z. Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine. Cancer Biol. Ther. 5 (2006) 959-964
85. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 19 (2000) 6627-6631
86. Hunter T., and Pines J. Cyclins and cancer. Cell 66 (1991) 1071-1074
87. Ivanchuk S.M., Mondal S., Dirks P.B., and Rutka J.T. The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. J. Neurooncol. 51 (2001) 219-229
88. Jackson J.G., and Pereira-Smith O.M. Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol. Cell. Biol. 26 (2006) 2501-2510
89. James M.C., and Peters G. Alternative product of the p16/CKDN2A locus connects the Rb and p53 tumor suppressors. Prog. Cell Cycle Res. 4 (2000) 71-81
90. Janumyan Y.M., Sansam C.G., Chattopadhyay A., Cheng N., Soucie E.L., Penn L.Z., Andrews D., Knudson C.M., and Yang E. Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. EMBO J. 22 (2003) 5459-5470
91. Jeffrey P.D., Tong L., and Pavletich N.P. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. Genes Dev. 14 (2000) 3115-3125
92. Jenkins R.B., Qian J., Lieber M.M., and Bostwick D.G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 57 (1997) 524-531
93. Johnson D.G., and Walker C.L. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 295-312
94. Johnston J.B., Navaratnam S., Pitz M.W., Maniate J.M., Wiechec E., Baust H., Gingerich J., Skliris G.P., Murphy L.C., and Los M. Targeting the EGFR pathway for cancer therapy. Curr. Med. Chem. 13 (2006) 3483-3492
95. Jones S.M., Klinghoffer R., Prestwich G.D., Toker A., and Kazlauskas A. PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1. Curr. Biol. 9 (1999) 512-521
96. Kaldis P., and Aleem E. Cell cycle sibling rivalry: Cdc2 vs. Cdk2. Cell Cycle 4 (2005) 1491-1494
97. Kandel E.S., Skeen J., Majewski N., Di Cristofano A., Pandolfi P.P., Feliciano C.S., Gartel A., and Hay N. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol. Cell. Biol. 22 (2002) 7831-7841
98. Kane L.P., Shapiro V., Stokoe D., and Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr. Biol. 9 (1999) 601-604
99. Khosravi-Far R., and Esposti M.D. Death receptor signals to mitochondria. Cancer Biol. Ther. 3 (2004) 1051-1057
100. Kim R., Emi M., and Tanabe M. Role of mitochondria as the gardens of cell death. Cancer Chemother. Pharmacol. 57 (2006) 545-553
101. Knudsen E.S., and Knudsen K.E. Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp. Biol. Med. (Maywood) 231 (2006) 1271-1281
102. Koff A., Cross F., Fisher A., Schumacher J., Leguellec K., Philippe M., and Roberts J.M. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66 (1991) 1217-1228
103. Konishi Y., Lehtinen M., Donovan N., and Bonni A. Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol. Cell 9 (2002) 1005-1016
104. Kops G.J., de Ruiter N.D., De Vries-Smits A.M., Powell D.R., Bos J.L., and Burgering B.M. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398 (1999) 630-634
105. Kranenburg O., van der Eb A.J., and Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J. 15 (1996) 46-54
106. Kreuter M., Langer C., Kerkhoff C., Reddanna P., Kania A.L., Maddika S., Chlichlia K., Bui T.N., and Los M. Stroke, myocardial infarction, acute and chronic inflammatory diseases: caspases and other apoptotic molecules as targets for drug development. Arch. Immunol. Ther. Exp. 52 (2004) 141-155
107. Kroczak T.J., Baran J., Pryjma J., Siedlar M., Rashedi I., Hernandez E., Alberti E., Maddkia S., and Los M. The emerging importance of DNA mapping and other comprehensive screening techniques as tools to identify new drug targets and as a mean of (cancer) therapy personalization. Expert Opin. Ther. Targets 10 (2006) 289-302
108. Krzemieniecki K., Szpyt E., Rashedi I., Gawron K., and Los M. Targeting of solid tumors and blood malignancies by antibody-based therapies. Central Eur. J. Biol. 1 (2006) 167-182
109. Lanave C., Santamaria M., and Saccone C. Comparative genomics: the evolutionary history of the Bcl-2 family. Gene 333 (2004) 71-79
110. Latres E., Malumbres M., Sotillo R., Martin J., Ortega S., Martin-Caballero J., Flores J.M., Cordon-Cardo C., and Barbacid M. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 19 (2000) 3496-3506
111. Lee H.H., Dadgostar H., Cheng Q., Shu J., and Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 9136-9141
112. Lee S.B., Cho E.S., Yang H.S., Kim H., and Um H.D. Serum withdrawal kills U937 cells by inducing a positive mutual interaction between reactive oxygen species and phosphoinositide 3-kinase. Cell Signal 17 (2005) 197-204
113. Lee W.H., Bookstein R., Hong F., Young L.J., Shew J.Y., and Lee E.Y. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235 (1987) 1394-1399
114. Li X., Zhang Z., Beiter T., and Schluesener H.J. Nanovesicular vaccines: exosomes. Arch. Immunol. Ther. Exp. (Warsz) 53 (2005) 329-335
115. Li Y., Dowbenko D., and Lasky L.A. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J. Biol. Chem. 277 (2002) 11352-11361
116. Liang J., and Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2 (2003) 339-345
117. Loeffler M., and Kroemer G. The mitochondrion in cell death control: certainties and incognita. Exp. Cell Res. 256 (2000) 19-26
118. Los M., and Gibson S. Apoptotic Pathways as Target for Novel Therapies of Cancer and Other Diseases (2005), Springer, New York
119. Los M., Stroh C., Janicke R.U., Engels I.H., and Schulze Osthoff K. Caspases: more than just killers?. Trends Immunol. 22 (2001) 31-34
120. Los M., van de Craen M., Penning C.L., Schenk H., Westendorp M., Baeuerle P.A., Dröge W., Krammer P.H., Fiers W., and Schulze-Osthoff K. Requirement of an ICE/Ced-3 protease for Fas/Apo-1-1mediated apoptosis. Nature 371 (1995) 81-83
121. Los M., Wesselborg S., and Schulze-Osthoff K. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity 10 (1999) 629-639
122. Lu B., Wang L., Stehlik C., Medan D., Huang C., Hu S., Chen F., Shi X., and Rojanasakul Y. Phosphatidylinositol 3-kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal Cl41 cells. J. Immunol. 176 (2006) 6785-6793
123. Maddika S., Booy E.P., Johar D., Gibson S.B., Ghavami S., and Los M. Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell death mediators by a Nur77-dependent pathway. J. Cell Sci. 118 (2005) 4485-4493
124. Maddika S., Mendoza F.J., Hauff K., Zamzow C.R., Paranjothy T., and Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol. Ther. 5 (2006) 10-19
125. Maehara K., Yamakoshi K., Ohtani N., Kubo Y., Takahashi A., Arase S., Jones N., and Hara E. Reduction of total E2F/DP activity induces senescence-like cell cycle arrest in cancer cells lacking functional pRB and p53. J. Cell Biol. 168 (2005) 553-560
126. Mamillapalli R., Gavrilova N., Mihaylova V.T., Tsvetkov L.M., Wu H., Zhang H., and Sun H. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr. Biol. 11 (2001) 263-267
127. Marte B.M., and Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci. 22 (1997) 355-358
128. Mashima T., and Tsuruo T. Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist. Updates 8 (2005) 339-343
129. Mayo L.D., and Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 11598-11603
130. Mazumder S., DuPree E.L., and Almasan A. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr. Cancer Drug Targets 4 (2004) 65-75
131. Mazumder S., Gong B., Chen Q., Drazba J.A., Buchsbaum J.C., and Almasan A. Proteolytic cleavage of cyclin E leads to inactivation of associated kinase activity and amplification of apoptosis in hematopoietic cells. Mol. Cell. Biol. 22 (2002) 2398-2409
132. Medema R.H., Kops G.J., Bos J.L., and Burgering B.M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404 (2000) 782-787
133. Meikrantz W., Gisselbrecht S., Tam S.W., and Schlegel R. Activation of cyclin A-dependent protein kinases during apoptosis. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3754-3758
134. Mendelsohn A.R., Hamer J.D., Wang Z.B., and Brent R. Cyclin D3 activates Caspase 2, connecting cell proliferation with cell death. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 6871-6876
135. Mendoza F.J., Espino P.S., Cann K.L., Bristow N., McCrea K., and Los M. Anti-tumor chemotherapy utilizing peptide-based approaches-apoptotic pathways, kinases, and proteasome as targets. Arch. Immunol. Ther. Exp. 53 (2005) 47-60
136. Morgan D.O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell. Dev. Biol. 13 (1997) 261-291
137. Nesbit C.E., Grove L.E., Yin X., and Prochownik E.V. Differential apoptotic behaviors of c-myc, N-myc, and L-myc oncoproteins. Cell Growth Differ. 9 (1998) 731-741
138. Nimbalkar D., Henry M.K., and Quelle F.W. Cytokine activation of phosphoinositide 3-kinase sensitizes hematopoietic cells to cisplatin-induced death. Cancer Res. 63 (2003) 1034-1039
139. Nourse J., Firpo E., Flanagan W.M., Coats S., Polyak K., Lee M.H., Massague J., Crabtree G.R., and Roberts J.M. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372 (1994) 570-573
140. Okada H., and Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 4 (2004) 592-603
141. Okamoto K., and Prives C. A role of cyclin G in the process of apoptosis. Oncogene 18 (1999) 4606-4615
142. Oliver L., and Vallette F.M. The role of caspases in cell death and differentiation. Drug Resist. Updates 8 (2005) 163-170
143. Ono K., Iwanaga Y., Hirayama M., Kawamura T., Sowa N., and Hasegawa K. Contribution of caveolin-1 alpha and Akt to TNF-alpha-induced cell death. Am. J. Physiol. Lung Cell. Mol. Physiol. 287 (2004) L201-L209
144. Ortega S., Prieto I., Odajima J., Martin A., Dubus P., Sotillo R., Barbero J.L., Malumbres M., and Barbacid M. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35 (2003) 25-31
145. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., Yew P.R., Draetta G.F., and Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269 (1995) 682-685
146. Palozza P., Serini S., Maggiano N., Angelini M., Boninsegna A., Di Nicuolo F., Ranelletti F.O., and Calviello G. Induction of cell cycle arrest and apoptosis in human colon adenocarcinoma cell lines by beta-carotene through down-regulation of cyclin A and Bcl-2 family proteins. Carcinogenesis 23 (2002) 11-18
147. Panigrahi S., and Mai S. Telomeres, genomic instability, DNA repair and breast cancer. Curr. Med. Chem. Anti-Inflamm. Anti-Allergy Agents 4 (2005) 421-428
148. Park M.-T., and Lee S.-J. Celll cycle and cancer. J. Biochem. Mol. Biol. 23 (2003) 60-65
149. Penn L.J., Brooks M.W., Laufer E.M., and Land H. Negative autoregulation of c-myc transcription. EMBO J. 9 (1990) 1113-1121
150. Phelps D.E., Hsiao K.M., Li Y., Hu N., Franklin D.S., Westphal E., Lee E.Y., and Xiong Y. Coupled transcriptional and translational control of cyclin-dependent kinase inhibitor p18INK4c expression during myogenesis. Mol. Cell. Biol. 18 (1998) 2334-2343
151. Philchenkov A., Zavelevich M., Kroczak T.J., and Los M. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp. Oncol. 26 (2004) 82-97
152. Pines J., and Hunter T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 58 (1989) 833-846
153. Porter L.A., Cukier I.H., and Lee J.M. Nuclear localization of cyclin B1 regulates DNA damage-induced apoptosis. Blood 101 (2003) 1928-1933
154. Porter L.A., Singh G., and Lee J.M. Abundance of cyclin B1 regulates gamma-radiation-induced apoptosis. Blood 95 (2000) 2645-2650
155. Prendergast G.C. Mechanisms of apoptosis by c-Myc. Oncogene 18 (1999) 2967-2987
156. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., and Reusch J.E. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 275 (2000) 10761-10766
157. Reed J.C. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 34 Suppl 5 (1997) 9-19
158. Reusch J.E., and Klemm D.J. Inhibition of cAMP-response element-binding protein activity decreases protein kinase B/Akt expression in 3T3-L1 adipocytes and induces apoptosis. J. Biol. Chem. 277 (2002) 1426-1432
159. Reynisdottir I., Polyak K., Iavarone A., and Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 9 (1995) 1831-1845
160. Rodriguez J.M., Glozak M.A., Ma Y., and Cress W.D. Bok, Bcl-2-related Ovarian Killer, Is cell cycle-regulated and sensitizes to stress-induced apoptosis. J. Biol. Chem. 281 (2006) 22729-22735
161. Romashkova J.A., and Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401 (1999) 86-90
162. Rowinsky E.K. Targeted induction of apoptosis in cancer managment: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J. Clin. Oncol. 23 (2005) 9394-9405
163. Rupnow B.A., Murtha A.D., Alarcon R.M., Giaccia A.J., and Knox S.J. Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res. 58 (1998) 1779-1784
164. Salazar G., Joshi A., Liu D., Wei H., Persson J.L., and Wolgemuth D.J. Induction of apoptosis involving multiple pathways is a primary response to cyclin A1-deficiency in male meiosis. Dev. Dyn. 234 (2005) 114-123
165. Schafer K.A. The cell cycle: a review. Vet. Pathol. 35 (1998) 461-478
166. Schwartz G.K., and Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol. 23 (2005) 9408-9421
167. Shack S., Wang X.T., Kokkonen G.C., Gorospe M., Longo D.L., and Holbrook N.J. Caveolin-induced activation of the phosphatidylinositol 3-kinase/Akt pathway increases arsenite cytotoxicity. Mol. Cell. Biol. 23 (2003) 2407-2414
168. Sheiness D., Fanshier L., and Bishop J.M. Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29. J. Virol. 28 (1978) 600-610
169. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
170. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell. Biol. 2 (2001) 731-737
171. Shi L., Chen G., He D., Bosc D.G., Litchfield D.W., and Greenberg A.H. Granzyme B induces apoptosis and cyclin A-associated cyclin-dependent kinase activity in all stages of the cell cycle. J. Immunol. 157 (1996) 2381-2385
172. Shi Y., Glynn J.M., Guilbert L.J., Cotter T.G., Bissonnette R.P., and Green D.R. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257 (1992) 212-214
173. Shim H., Chun Y.S., Brian C., Lewis B.C., and Dang C.V. A unique glucose-dependent apoptotic pathway inducedbyc-Myc. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 1511-1516
174. Shimizu T., O'Connor P.M., Kohn K.W., and Pommier Y. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res. 55 (1995) 228-231
175. Shin I., Yakes F.M., Rojo F., Shin N.Y., Bakin A.V., Baselga J., and Arteaga C.L. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med. 8 (2002) 1145-1152
176. Shtivelman E., Sussman J., and Stokoe D. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr. Biol. 12 (2002) 919-924
177. Siegel R.M. Caspases at the crossroads of immune-cell life and death. Nat. Rev. Immunol. 6 (2006) 308-317
178. Smith M.L., Kontny H.U., Bortnick R., and Fornace Jr. A.J. The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Exp. Cell Res. 230 (1997) 61-68
179. Sofer-Levi Y., and Resnitzky D. Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E. Oncogene 13 (1996) 2431-2437
180. Spencer C.A., and Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res. 56 (1991) 1-48
181. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., and Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 (1998) 29-39
182. Steiner P., Rudolph B., Muller D., and Eilers M. The functions of Myc in cell cycle progression and apoptosis. Prog. Cell Cycle Res. 2 (1996) 73-82
183. Stroh C., Cassens U., Samraj A.K., Sibrowski W., Schulze-Osthoff K., and Los M. The role of caspases in cryoinjury: caspase inhibition strongly improves the recovery of cryopreserved hematopoietic and other cells. FASEB J. 16 (2002) 1651-1653
184. Sweeney C., Murphy M., Kubelka M., Ravnik S.E., Hawkins C.F., Wolgemuth D.J., and Carrington M. A distinct cyclin A is expressed in germ cells in the mouse. Development 122 (1996) 53-64
185. Tenjo T., Toyoda M., Okuda J., Watanabe I., Yamamoto T., Tanaka K., Ohtani M., Nohara T., Kawasaki H., and Tanigawa N. Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology 58 (2000) 45-51
186. Vairo G., Soos T.J., Upton T.M., Zalvide J., DeCaprio J.A., Ewen M.E., Koff A., and Adams J.M. Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation. Mol. Cell. Biol. 20 (2000) 4745-4753
187. Vanhaesebroeck B., and Alessi D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346 Pt 3 (2000) 561-576
188. Vassilev L.T., Tovar C., Chen S., Knezevic D., Zhao X., Sun H., Heimbrook D.C., and Chen L. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 10660-10665
189. Vennstrom B., Sheiness D., Zabielski J., and Bishop J.M. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J. Virol. 42 (1982) 773-779
190. Vermeulen K., Van Bockstaele D.R., and Berneman Z.N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36 (2003) 131-149
191. Vieira H.L., Boya P., Cohen I., El Hamel C., Haouzi D., Druillenec S., Belzacq A.S., Brenner C., Roques B., and Kroemer G. Cell permeable BH3-peptides overcome the cytoprotective effect of Bcl-2 and Bcl-X(L). Oncogene 21 (2002) 1963-1977
192. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
193. Wadler S. Perspectives for cancer therapies with cdk2 inhibitors. Drug Resist. Updates 4 (2001) 347-367
194. Walensky L.D., Kung A.L., Escher I., Malia T.J., Barbuto S., Wright R.D., Wagner G., Verdine G.L., and Korsmeyer S.J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305 (2004) 1466-1470
195. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., and Baldwin Jr. A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281 (1998) 1680-1683
196. Wang J.M., Chao J.R., Chen W., Kuo M.L., Yen J.J., and Yang-Yen H.F. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell. Biol. 19 (1999) 6195-6206
197. Watson A.J.M. An overview of apoptosis and the prevention of colorectal cancer. Crit. Rev. Oncol. Hematol. 57 (2006) 107-121
198. Wechsler-Reya R., Elliott K., Herlyn M., and Prendergast G.C. The putative tumor suppressor BIN1 is a short-lived nuclear phosphoprotein, the localization of which is altered in malignant cells. Cancer Res. 57 (1997) 3258-3263
199. Wesselborg S., and Lauber K. Mechanism of anticancer drug action. In: Los M., and Gibson S.B. (Eds). Apoptotic Pathways as Target for Novel Therapies in Cancer and Other Diseases (2005), Springer Academic Press, New York
200. Wolowiec D., Deviller P., Simonin D., Souchier C., Rimokh R., Benchaib M., Bryon P.A., and Ffrench M. Cdk1 is a marker of proliferation in human lymphoid cells. Int J Cancer 61 (1995) 381-388
201. Yan Y., Frisen J., Lee M.H., Massague J., and Barbacid M. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 11 (1997) 973-983
202. Yang L., Li N., Wang C., Yu Y., Yuan L., Zhang M., and Cao X. Cyclin L2, a novel RNA polymerase II-associated cyclin, is involved in pre-mRNA splicing and induces apoptosis of human hepatocellular carcinoma cells. J. Biol. Chem. 279 (2004) 11639-11648
203. You H., Pellegrini M., Tsuchihara K., Yamamoto K., Hacker G., Erlacher M., Villunger A., and Mak T.W. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J. Exp. Med. 203 (2006) 1657-1663
204. Yu Q. Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. Drug Resist. Updates 9 (2006) 19-25
205. Yuan J., Yan R., Kramer A., Eckerdt F., Roller M., Kaufmann M., and Strebhardt K. Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 23 (2004) 5843-5852
206. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., and Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3 (2001) 245-252
207. Zindy F., Quelle D.E., Roussel M.F., and Sherr C.J. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15 (1997) 203-211
208. Zinkel S., Gross A., and Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 13 (2006) 1351-1359